Breakdowns In The Breakthrough Lane: When Recipients Of FDA Expedited Designation Fall Short
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.